Dopamine ( DRD 2 ) and Serotonin ( HTR 2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia
Résumé
Treatment response to antipsychotic drugs is variable and conflicting results have been obtained while studying the influence of DRD2 and HTR2 genetic variants on antipsychotic drug efficacy. To explore further, the present study aimed to assess the influence of DRD2-141 C Ins/Del, Taq1A and HTR2A-1438 G/A, 102T/C and HTR2C-759 C/T genetic polymorphisms in response to risperidone in patients with schizophrenia. The study was conducted among the n=320 South Indian patients with schizophrenia who received risperidone treatment (4-8 mg per day) for a minimum of four weeks. Genotyping was done by real-time PCR. Antipsychotic response was assessed using CGI-I score in cross-sectional group, PANSS score in prospective group at baseline and after receiving the risperidone therapy.
Mots clés
DRD2 -141 C Ins/Del (n=310
Ins/Ins=177
Ins/Del+ Del/Del=133
OR 0.70
95% CI 0.4-1.2 p 0.2)
Taq1A (n=320
AA=35
AG=132
GG=153
p 0.2)
HTR2A -1438 G/A (n=320
AA=39
AG=164
GG=117
HTR2A 102T/C (n=320
CC=115
CT=165
TT=40
p 0.1) HTR2C -759 C/T (females n=132
CC=65
CT+TT=67
OR 1.3
95% CI 0.6-2.8
p 0.5
males n=186
C=120
T=66
OR 1.2
95% CI 0.6-2.4
p 0.4) genetic polymorphisms did not show any association with antipsychotic response to risperidone. DRD2 -141 C Ins/Del
Taq1A
HTR2A -1438 G/A
102T/C and Risperidone
Schizophrenia
Dopamine
Serotonin
Genetic Polymorphism
Fichier principal
Alladi_et_al-2018-Fundamental &_Clinical_Pharmacology.pdf (486.53 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)